{"component": "definition", "props": {"groups": [{"size": 74, "snippet_links": [], "samples": [{"hash": "4t2otvzT1D3", "uri": "/contracts/4t2otvzT1D3#antibody", "label": "Collaboration Agreement (Elevation Oncology, Inc.)", "score": 32.364818573, "published": true}, {"hash": "dXYCvUHS7Nt", "uri": "/contracts/dXYCvUHS7Nt#antibody", "label": "Technology Transfer and License Agreement (Dyax Corp)", "score": 25.3312797546, "published": true}, {"hash": "2U9EjwXCLjP", "uri": "/contracts/2U9EjwXCLjP#antibody", "label": "Collaboration Agreement (Merrimack Pharmaceuticals Inc)", "score": 22.8151950836, "published": true}], "snippet": "means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.", "hash": "275918c0adcdaa579eb26806c7030366", "id": 1}, {"size": 37, "snippet_links": [], "samples": [{"hash": "jbFnhvhBxSn", "uri": "/contracts/jbFnhvhBxSn#antibody", "label": "Antibody Discovery Agreement (Apogee Therapeutics, Inc.)", "score": 37.4709103354, "published": true}, {"hash": "d8k8heotZfA", "uri": "/contracts/d8k8heotZfA#antibody", "label": "License Agreement (Apogee Therapeutics, Inc.)", "score": 37.4709103354, "published": true}, {"hash": "iI9KVSrGWLi", "uri": "/contracts/iI9KVSrGWLi#antibody", "label": "Platform Option Agreement (Cyclerion Therapeutics, Inc.)", "score": 37.4353179932, "published": true}], "snippet": "means any molecule, including [***].", "hash": "1030e7f2a9f2821b89984bd5ccb4e107", "id": 2}, {"size": 24, "snippet_links": [{"key": "naturally-occurring", "type": "definition", "offset": [28, 47]}, {"key": "modification-of", "type": "clause", "offset": [123, 138]}, {"key": "the-foregoing", "type": "definition", "offset": [193, 206]}, {"key": "modified-versions", "type": "clause", "offset": [227, 244]}, {"key": "amino-acid", "type": "clause", "offset": [421, 431]}, {"key": "in-order-to", "type": "clause", "offset": [446, 457]}], "samples": [{"hash": "64eggMp03C1", "uri": "/contracts/64eggMp03C1#antibody", "label": "Collaboration and License Agreement (Xencor Inc)", "score": 36.1567420959, "published": true}, {"hash": "ep05kbNgvtr", "uri": "/contracts/ep05kbNgvtr#antibody", "label": "License Agreement (Zenas BioPharma, Inc.)", "score": 35.639289856, "published": true}, {"hash": "4zGlvFBByKW", "uri": "/contracts/4zGlvFBByKW#antibody", "label": "License Agreement (Zenas BioPharma, Inc.)", "score": 35.639289856, "published": true}], "snippet": "means any antibody, whether naturally occurring, artificially produced, raised in an artificial system, or created through modification of another antibody or otherwise; any fragment of any of the foregoing; and any chemically modified versions of the foregoing antibodies (including versions that are conjugated with another chemical entity, such as a drug or toxin; pegylated versions (regardless of whether containing amino acid substitutions in order to achieve pegylation); and other chemically modified versions).", "hash": "679cc5ebcaa2dc28d7827589ea79c844", "id": 3}, {"size": 24, "snippet_links": [{"key": "multispecific-antibody", "type": "definition", "offset": [84, 106]}, {"key": "single-chain-antibody", "type": "definition", "offset": [108, 129]}, {"key": "domain-antibody", "type": "definition", "offset": [133, 148]}, {"key": "other-source", "type": "clause", "offset": [280, 292]}], "samples": [{"hash": "lsJpsFd4WQ2", "uri": "/contracts/lsJpsFd4WQ2#antibody", "label": "License Agreement (Homology Medicines, Inc.)", "score": 34.9603004456, "published": true}, {"hash": "c2BSyhZ8IjG", "uri": "/contracts/c2BSyhZ8IjG#antibody", "label": "Collaboration and Option Agreement (Homology Medicines, Inc.)", "score": 34.9603004456, "published": true}, {"hash": "4eiQmjHF0gH", "uri": "/contracts/4eiQmjHF0gH#antibody", "label": "Asset Purchase Agreement (Homology Medicines, Inc.)", "score": 34.9603004456, "published": true}], "snippet": "means any antibody or antigen binding fragment thereof (including any bispecific or multispecific antibody, single chain antibody or domain antibody) and/or similar antigen binding protein, whether polyclonal, monoclonal, human, humanized, chimeric, murine, synthetic or from any other source.", "hash": "7ac827de3a63f7ce83bc33dd13ae9596", "id": 4}, {"size": 22, "snippet_links": [], "samples": [{"hash": "kB72ZcDtSi5", "uri": "/contracts/kB72ZcDtSi5#antibody", "label": "Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 34.1581115723, "published": true}, {"hash": "3anfNqVM1V1", "uri": "/contracts/3anfNqVM1V1#antibody", "label": "Research Collaboration and License Agreement (Mersana Therapeutics, Inc.)", "score": 33.3504447937, "published": true}, {"hash": "7dLpAbfENxy", "uri": "/contracts/7dLpAbfENxy#antibody", "label": "Commercial License and Option Agreement (Mersana Therapeutics, Inc.)", "score": 33.1587944031, "published": true}], "snippet": "means [**].", "hash": "d625c0c2cdb17b208fba7a69b82dd049", "id": 5}, {"size": 22, "snippet_links": [{"key": "other-source", "type": "clause", "offset": [116, 128]}], "samples": [{"hash": "e9TFvuw6o6f", "uri": "/contracts/e9TFvuw6o6f#antibody", "label": "Global License Agreement (Prothena Corp Public LTD Co)", "score": 34.8343582153, "published": true}, {"hash": "1PRlwCf6H1w", "uri": "/contracts/1PRlwCf6H1w#antibody", "label": "Master Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "jyCPZUGoLnP", "uri": "/contracts/jyCPZUGoLnP#antibody", "label": "Master Collaboration Agreement (Prothena Corp PLC)", "score": 29.6242294312, "published": true}], "snippet": "means any [***] antibody (including [***]), [***] whether human, humanized, chimeric, murine, synthetic or from any other source.", "hash": "f5a34975d6efef398fe5f6e7a58ecec7", "id": 6}, {"size": 19, "snippet_links": [{"key": "having-been", "type": "clause", "offset": [97, 108]}, {"key": "licensed-technology", "type": "clause", "offset": [126, 145]}, {"key": "future-generation-mice", "type": "definition", "offset": [184, 206]}, {"key": "amino-acid", "type": "clause", "offset": [269, 279]}], "samples": [{"hash": "j2okG8kYieV", "uri": "/contracts/j2okG8kYieV#antibody", "label": "Product License Agreement (Abgenix Inc)", "score": 18.0, "published": true}, {"hash": "cT3ZZK7v2du", "uri": "/contracts/cT3ZZK7v2du#antibody", "label": "Research License and Option Agreement (Abgenix Inc)", "score": 18.0, "published": true}, {"hash": "bIfgN9W1URl", "uri": "/contracts/bIfgN9W1URl#antibody", "label": "Master Research License and Option Agreement (Abgenix Inc)", "score": 18.0, "published": true}], "snippet": "means a composition comprising a whole antibody or a fragment thereof, said antibody or fragment having been derived from the Licensed Technology and/or generated from the Mice or the Future Generation Mice or having been derived from nucleotide sequences encoding, or amino acid sequences of, such an antibody or fragment.", "hash": "f7aa4c3fa7313b09f61e185e88c6d22c", "id": 7}, {"size": 15, "snippet_links": [{"key": "naturally-occurring", "type": "definition", "offset": [94, 113]}, {"key": "not-limited", "type": "clause", "offset": [201, 212]}, {"key": "a-portion", "type": "definition", "offset": [440, 449]}, {"key": "to-confer", "type": "definition", "offset": [490, 499]}], "samples": [{"hash": "1dOF1noIYvX", "uri": "/contracts/1dOF1noIYvX#antibody", "label": "Multi Target Agreement (Immunogen Inc)", "score": 26.6290206909, "published": true}, {"hash": "6oGNdK1nVTp", "uri": "/contracts/6oGNdK1nVTp#antibody", "label": "Multi Target Agreement (Immunogen Inc)", "score": 24.3429164886, "published": true}, {"hash": "51tsk10G1Ob", "uri": "/contracts/51tsk10G1Ob#antibody", "label": "Multi Target Agreement (Immunogen Inc)", "score": 23.773443222, "published": true}], "snippet": "means an antibody, whether polyclonal or monoclonal, multiple or single chain, recombinant or naturally occurring, whole or fragment, and any variants, derivatives or constructs thereof, including but not limited to, antigen binding portions including Fab, Fab\u2019, F(ab\u2019)2, Fv, dAb and CDR fragments, single chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides (including humanized versions thereof) that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to a polypeptide.", "hash": "574e1f78e4b0f0123ec3f597cce81b1e", "id": 8}, {"size": 14, "snippet_links": [], "samples": [{"hash": "az7L0fDPC3f", "uri": "https://www.ncmedboard.org/images/uploads/minutes_uploads/August_30_2004.pdf", "label": "www.ncmedboard.org", "score": 7.4038329124, "published": false}, {"hash": "95JwpsNyYxo", "uri": "https://www.ncleg.gov/documentsites/committees/JLAPOC/Licensing%20Board%20Submissions%20-%20NCGS%2093B/Medical%20Board/2013/Annual%20Report%20&%20Financial%20Statement/Annual%20Report%20&%20Financial%20Statement%20-%20Medical%20Board%20-%202013.pdf", "label": "www.ncleg.gov", "score": 5.3039016724, "published": false}, {"hash": "js3gA85ST0t", "uri": "https://files.nc.gov/ncoah/documents/Rules/NC-Register/NC-Register-Volume-28-Issue-21.pdf", "label": "files.nc.gov", "score": 5.1601643562, "published": false}], "snippet": "means a protein in the blood that is produced in response to stimulation by a specific antigen. Antibodies help destroy the antigen that produced them. Antibodies against an antigen usually equate to immunity to that antigen.", "hash": "8d3287c90754bab4f238a057bb51b738", "id": 9}, {"size": 13, "snippet_links": [{"key": "fusion-protein", "type": "definition", "offset": [168, 182]}, {"key": "other-source", "type": "clause", "offset": [405, 417]}, {"key": "including-without-limitation", "type": "clause", "offset": [420, 448]}, {"key": "to-confer", "type": "definition", "offset": [793, 802]}], "samples": [{"hash": "Yaln8Ql3jm", "uri": "/contracts/Yaln8Ql3jm#antibody", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.5242977142, "published": true}, {"hash": "2cJMHJMaGeT", "uri": "/contracts/2cJMHJMaGeT#antibody", "label": "Collaboration Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.5242977142, "published": true}, {"hash": "bwi1M2Friju", "uri": "/contracts/bwi1M2Friju#antibody", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.3709793091, "published": true}], "snippet": "means any antibody, any gene expressing such an antibody, any hybridoma producing such antibody, or any fragment, variant, derivative or construct thereof, or antibody fusion protein produced therefrom (including PEDgylated or multimeric versions thereof, whether polyclonal, monoclonal, multi-specific antibodies (e.g., bi-specific antibodies), human, humanized, chimeric, murine, synthetic, or from any other source), including without limitation (a) the full immunoglobin molecules (e.g. the IgG, IgM,IgE, IgA, and IgD molecules), and (b) the antigen binding portions including Fab, Fab', F(ab')2, Fv, dAb, and CDR fragments, chimeric antibodies, diabodies, polypeptides, linear antibodies and single-chain antibodies (scFv) that contain any portion of an immunoglobulin that is sufficient to confer specific binding to an antigen.", "hash": "35d8d4a4fe6ac0e340dd474b9382f0f5", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIRYW50aWJvZHkjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Antibody", "size": 851, "snippet": "means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.", "id": "antibody", "examples": ["Except to the extent required by Applicable Law or the rules of any stock exchange or listing agency, neither Party shall issue a press release announcing that the Parties have entered into an <strong>Antibody</strong> discovery partnership, without the other Party\u2019s prior written consent, which shall not be unreasonably withheld.", "Apogee and its Affiliates shall cause all of its and their employees who, in each case, generated, conceived of or created any Project <strong>Antibody</strong> Technology to assign [***] all ownership rights in such Project <strong>Antibody</strong> Technology to Paragon.", "Preparation, filing, prosecution, maintenance and enforcement of the Project <strong>Antibody</strong> Patents are addressed in the License Agreement.", "If \u2587\u2587\u2587\u2587\u2587\u2587\u2587 agrees, in its sole discretion, to perform the CMC Activities for the CMC Substitution Project <strong>Antibody</strong>, the Parties shall update the applicable Research Plan, a new CMC Fee and CMC Estimated Timeline shall apply to such CMC Activities, and any unpaid portion of the CMC Fee for the CMC Activities for the original CMC Project <strong>Antibody</strong> shall be waived.", "If the JDC makes such determination, Apogee shall have the one-time right, exercisable upon written notice within [***] days of the JDC\u2019s determination, to substitute the CMC Project <strong>Antibody</strong> with a different Project <strong>Antibody</strong> (such Project <strong>Antibody</strong>, the \u201cCMC Substitution Project <strong>Antibody</strong>\u201d).", "Subject to the rights and licenses granted to Apogee in this Agreement, as between the Parties, Paragon or its Affiliates shall own all right, title and interest in and to all Project <strong>Antibody</strong> Technology, irrespective of inventorship.", "For clarity, the CMC Fee (and corresponding CMC Monthly Fee) are established on a per-Project <strong>Antibody</strong> candidate basis, and CMC Activities for any additional candidate requires a separate selection of a CMC Activities Package and agreement on the corresponding CMC Estimated Timeline.", "Apogee shall execute and deliver, and shall cause its Affiliates to execute and deliver, such additional documents, instruments, conveyances and assurances and take any such further actions as may be [***] required to ensure that all right, title and interest in the Project <strong>Antibody</strong> Technology is effectively assigned to and held by Paragon.", "If Paragon does not agree to proceed with CMC Activities for the CMC Substitution Project <strong>Antibody</strong>, the Parties shall amend the Research Plan so that it does not require the performance of any CMC Activities or further payment of the CMC Fee.", "Paragon may update Exhibit B on a [***] basis by providing written notice thereof to Apogee at least [***] days prior to the end of [***], and such updated Exhibit B shall only apply to new CMC Activities (i.e., CMC Activities for the Research Program that have not previously been the subject of CMC Activities, or CMC Activities for a CMC Substitution Project <strong>Antibody</strong>)."], "related": [["antigen", "Antigen", "Antigen"], ["licensed-antibody", "Licensed Antibody", "Licensed <strong>Antibody</strong>"], ["receptor", "Receptor", "Receptor"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"]], "related_snippets": [], "updated": "2026-06-24T04:23:54+00:00"}, "json": true, "cursor": ""}}